Role of Anti???Interleukin-2 Receptor Antibodies in Kidney Transplantation
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 15 (10) , 655-666
- https://doi.org/10.2165/00063030-200115100-00003
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Interleukin 2 Leads to Dose-Dependent Expression of the Alpha Chain of the IL-2 Receptor on CD25-Negative T Lymphocytes in the Absence of Exogenous Antigenic StimulationClinical Immunology, 2000
- The effect of Daclizumab in a high‐risk renal transplant populationClinical Transplantation, 2000
- Efficacy of Daclizumab in an African-American and Hispanic renal transplant populationTransplant International, 2000
- Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysisTransplant International, 2000
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- A PHASE I TRIAL OF HUMANIZED ANTI-INTERLEUKIN 2 RECEPTOR ANTIBODY IN RENAL TRANSPLANTATION1Transplantation, 1997
- PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL ANTIBODY USED IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1995
- A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATIONTransplantation, 1995
- Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal AllograftsNew England Journal of Medicine, 1990
- T-Lymphocyte-Antigen Interactions in Transplant RejectionNew England Journal of Medicine, 1990